EGFR and neoplasm: We noted some mutations that have been reported to affect immune–tumor interactions; for instance, the mutation frequency of EGFR ranged from 15% in the high-risk group to 39% in the low-risk group, while the frequency of mutations in TP53 and PTEN ranged from 36% to 33% in the high-risk group to 29% and 25% in the low-risk group (Figure 5A).